Over 650 million people worldwide face obesity or type 2 diabetes, conditions sharing biological pathways that accelerate each other. Traditional treatments struggle to address both simultaneously. Bioglutide NA-931, an oral small molecule quadruple receptor agonist, activates GCGR, GIPR, GLP-1R, and IGF-1R simultaneously. This multi-target approach mimics natural metabolic regulation, addressing the vicious cycle where excess fat impairs insulin sensitivity while glucose dysfunction promotes fat accumulation through coordinated weight loss, glycemic control, thermogenesis, and metabolic flexibility.
Bioglutide NA-931
1.General Specification(in stock)
(1)API(Pure powder)
PE/Al foil bag/ paper box for Pure powder
(2)Spot-On
(3)Solution
(4)Drops
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Product Code:BM-1-154
NA-931
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-3
Manufacturer: BLooM TECH Wuxi Factory
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK,
New Zealand , Canada etc.
We provide bioglutide NA-931, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/synthetic-chemical/peptide/bioglutide-na-931.html
How Bioglutide NA-931 Targets Shared Pathways in Obesity and Type 2 Diabetes?
The Interconnected Nature of Metabolic Dysfunction
Obesity and type 2 diabetes share common pathophysiological nprocesses including chronic inflammation, mitochondrial dysfunction, and disrupted hormone signaling. Adipose tissue releases pro-inflammatory cytokines impairing insulin pathways, leading to compensatory hyperinsulinemia that eventually exhausts pancreatic beta cells. Visceral fat releases free fatty acids into portal circulation, overworking hepatic metabolism and driving insulin resistance.
Bioglutide NA-931 addresses these root causes through coordinated four-receptor activation.
Hormonal Coordination Through Multi-Receptor Engagement
The metabolic system relies on coordinated hormone signaling across multiple pathways. Single-target therapies often trigger compensatory responses limiting effectiveness. Bioglutide NA-931 activates receptors that naturally work together for metabolic control.
GIPR enhances GLP-1R effects on adipose tissue function while reducing gastrointestinal side effects. GCGR stimulation increases energy expenditure through thermogenesis when balanced by concurrent GLP-1R and IGF-1R activation preventing glucose elevation.
Breaking the Insulin Resistance Cycle
Insulin resistance links obesity to type 2 diabetes through progressive beta cell exhaustion.
Bioglutide NA-931 breaks this cycle through IGF-1R activation improving insulin sensitivity via PI3K-Akt signaling. GIPR and GLP-1R promote healthy adipokine release with increased adiponectin and reduced leptin resistance. This anti-inflammatory action decreases kinase activity interfering with insulin receptor function, restoring normal metabolic signaling and reducing pancreatic workload.
Bioglutide NA-931 Mechanism for Dual Metabolic Condition Support
Central Appetite Regulation and Peripheral Metabolic Effects
Hypothalamic GLP-1 receptors control craving and vitality adjust. Bioglutide NA-931 actuates these receptors, improving POMC neuron action whereas smothering NPY and AgRP neurons. This makes satiety signals decreasing starvation without extreme queasiness.Multi-receptor enactment produces more middle of the road craving concealment than single-target compounds. Concurrent fringe impacts advance fat lipolysis through GIPR and GLP-1R whereas GCGR quickens hepatic greasy corrosive oxidation.
Pancreatic Function Preservation and Enhancement
Beta cell wellbeing decides long-term metabolic results. GLP-1R actuation ensures beta cells by expanding glucose-stimulated affront discharge, advancing expansion, and restraining apoptosis.GIPR improves beta cell work through complementary pathways. Double incretin receptor actuation gives prevalent glycemic control. Glucose-dependent affront emission diminishes hypoglycemia hazard compared to sulfonylureas, as affront discharge diminishes when blood glucose normalizes indeed amid caloric restriction.
Energy Expenditure and Metabolic Rate Enhancement
Sustainable weight misfortune requires keeping up vitality consumption amid calorie confinement. Versatile thermogenesis regularly moderates digestion system, undermining results.GCGR actuation raises basal metabolic rate through hepatic vitality utilization and brown fat thermogenesis by means of UCP1 expression. IGF-1R jam incline body mass through expanded protein union and decreased breakdown. This anticipates the metabolic lull and utilitarian decay ordinary of customary weight misfortune approaches.
Why Bioglutide NA-931 Addresses Both Weight and Glucose Regulation Together?
Synergistic Effects on Metabolic Flexibility
Metabolic flexibility enables efficient switching between carbohydrate and fat oxidation. This capacity is lost in obesity and diabetes. GCGR activation accelerates fat oxidation during fasting while GLP-1R and GIPR enhance glucose disposal post-meal. This balanced approach prevents ectopic lipid accumulation in liver, muscle, and pancreas. Restored flexibility improves both weight management and glycemic control across fasting and feeding states.
Reduction of Hepatic Glucose Production
The liver balances glucose production and storage, but insulin resistance causes excessive gluconeogenesis and fasting hyperglycemia. GLP-1R activation improves hepatic insulin sensitivity, restoring normal suppression of glucose production. The compound normalizes insulin-to-glucagon ratios through alpha cell effects. Despite GCGR activation, coordinated multi-pathway engagement prevents hyperglycemia through enhanced glucose disposal and insulin sensitivity improvements across tissues.
Cardiovascular and Metabolic Risk Reduction
Obesity and diabetes increase cardiovascular risk through dyslipidemia, hypertension, and endothelial dysfunction. Bioglutide NA-931 reduces blood pressure through weight loss, improves lipid profiles with lower triglycerides and higher HDL, and decreases inflammatory markers. GLP-1R may provide direct cardiac protection through receptors in heart tissue. These combined effects suggest significant potential for reducing overall cardiovascular disease risk.
How Bioglutide NA-931 Supports Energy Balance in Metabolic Disorders?
Adipose Tissue Remodeling and Function
Visceral adipose tissue releases inflammatory adipokines and free fatty acids driving insulin resistance. Bioglutide NA-931 preferentially reduces abdominal fat through GCGR-mediated lipolysis and improved insulin sensitivity. Beyond quantity, adipose tissue quality improves with better vascularization, reduced immune cell infiltration, and normalized adipocyte function. This remodeling creates healthier metabolic signaling patterns and reduces systemic inflammation.
Muscle Tissue Preservation and Metabolic Contribution
Skeletal muscle is the primary site for glucose disposal and contributes significantly to basal metabolic rate. IGF-1R activation preserves muscle mass during weight loss through enhanced protein synthesis and reduced degradation. Clinical trials show lean mass preservation distinguishing this compound from dieting or single-target GLP-1 agonists. Maintaining muscle supports metabolic rate, functional capacity, and improved post-meal glucose disposal.
Mitochondrial Function and Oxidative Capacity
Mitochondrial dysfunction underlies metabolic disease through reduced oxidative capacity and increased reactive oxygen species. IGF-1R activation stimulates PGC-1α, a master regulator of mitochondrial biogenesis, increasing mitochondrial density in muscle and other tissues. This improves glucose and fatty acid oxidation while reducing partially oxidized lipid accumulation. Enhanced mitochondrial efficiency lowers oxidative stress, addressing fundamental cellular defects driving disease.
Bioglutide NA-931 Role in Integrated Obesity and Diabetes Management
Patient-Centered Therapeutic Advantages
Treatment adherence remains challenging with injectable medications. Oral bioglutide NA-931 eliminates needle discomfort and dosing complexity. Patients often prefer oral administration, potentially increasing treatment initiation and persistence.Multi-target effects provide comprehensive improvements across weight, glucose, energy, and mood, creating positive feedback reinforcing adherence. This contrasts with single-target therapies addressing limited aspects of patient health concerns.
Clinical Application Across the Metabolic Disease Spectrum
Bioglutide NA-931 addresses metabolic disease from prediabetes with obesity to advanced type 2 diabetes. Early intervention may prevent diabetes progression through concurrent weight loss,insulin sensitivity improvement, and beta cell preservation. For established diabetes, the compound serves as monotherapy or combination with metformin or SGLT2 inhibitors. As metabolic function improves, other medications may be reduced or discontinued.
Long-Term Disease Modification Potential
Current treatments manage symptoms without altering disease course, with metabolic deterioration resuming after discontinuation. Bioglutide NA-931 may modify disease through preserved beta cell mass and function. Improved adipose tissue and muscle mass could sustain metabolic gains post-treatment. Weight loss initiates positive metabolic cycles reducing inflammation and improving insulin sensitivity. Long-term studies are needed to confirm disease-modifying potential.
Conclusion
The combination of obesity and type 2 diabetes is one of the biggest public health problems of our time. It affects hundreds of millions of people around the world and puts a huge strain on budgets, healthcare systems, and people's quality of life. Traditional treatments that focus on these conditions independently or through single processes have only partially helped, but they haven't been able to fully fix the complicated metabolic problems that cause both diseases.
Bioglutide NA-931 is a completely new way to treat metabolic diseases because it works by activating four receptors at once, which has never been done before. This new molecule recreates the coordinated hormonal signaling that is necessary for good metabolic control by activating GCGR, GIPR, GLP-1R, and IGF-1R all at the same time. The outcome is a complete metabolic change that tackles weight, glucose control, insulin sensitivity, beta cell function, energy usage, muscle preservation, and cardiovascular risk factors all at the same time.
So far, clinical data shows that it works very well across a number of metabolic measures and is safe and well tolerated. Oral dosing gets around some of the big problems that patients have with injectable medicines, which could help them start treatment and stick with it for a long time. Bioglutide NA-931 could change the way metabolic diseases are treated and give millions of patients a better, more convenient, and all-around treatment choice as it moves through later stages of clinical testing.
The creation of the substance is part of a larger trend in pharmaceutical innovation toward methods that work on multiple targets and are more like how living things work. Instead of looking for "magic bullets" that can only affect one thing, drug development today is more and more aware that complicated diseases need complicated treatments. Bioglutide NA-931 is a good example of this idea because it shows that carefully planned multi-target drugs can have effects that are greater than the sum of their parts.
FAQ
1. What makes Bioglutide NA-931 different from existing diabetes and obesity medications?
+
-
Bioglutide NA-931 is special because it targets GCGR, GIPR, GLP-1R, and IGF-1R all at the same time using a unique quadruple receptor activation process. When compared to single-target treatments, this multi-target method controls the metabolism more completely. The chemical helps with more than just controlling glucose and losing weight. It also helps with keeping muscles, burning energy, and making the metabolism more flexible. Additionally, its oral form is much more convenient than injectable versions, which could help patients stick with their treatment and improve results.
2. Can Bioglutide NA-931 be used by patients with only obesity or only type 2 diabetes, or is it specifically for those with both conditions?
+
-
Although the substance was created to help people with both types of metabolic conditions, its way of working can help people who only have type 2 diabetes or obesity. People who are overweight but have normal glucose metabolism would gain from the compound's effects on metabolic rate, energy usage, and appetite suppression. In the same way, people with type 2 diabetes who are not very overweight could benefit from better insulin production, better insulin sensitivity, and defense of beta cells. The compound's ability to work with a wide range of metabolic diseases means it could be useful for many types of patients.
3. What is the safety profile of Bioglutide NA-931, particularly regarding gastrointestinal side effects common with similar medications?
+
-
Partner with BLOOM TECH - Your Trusted Bioglutide NA-931 Supplier
Need a dependable bioglutide NA-931 supplier to help with your study, development, or business production? Shaanxi BLOOM TECH Co., Ltd. is ready to be your all-around partner. They have been making organic chemicals and medicinal intermediates for more than 12 years. Our 100,000-square-meter GMP-certified factories meet the standards of the US FDA, the EU, Japan, and China. This means that you can be sure you'll get the best materials for your most important projects.
As approved providers to 24 well-known foreign businesses in the biotechnology, pharmaceutical, and specialty chemical industries, we provide more than just goods. Our quality assurance method has three levels: testing in the plant, internal QA/QC checks, and third-party approval. This guarantees that every batch meets the necessary standards. We offer clear pricing with set profit margins, accurate lead times tracked through our ERP system, and all the documents you need for easy customs approval around the world.
BLOOM TECH provides flexible, expandable supply chains that fit your schedule and budget, whether you need small amounts for early research or large amounts for clinical studies and business production. Our technical help team is quick to answer questions and works with you to solve problems so you can reach your R&D goals quickly.
Connect with our team today at [Sales@bloomtechz.com] to talk about how we can help with your bioglutide NA-931 needs and move your metabolic disease study forward with quality and reliability you can count on.
References
1. Tran LL. 2189-LB: Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese with at Least One Weight-Related Comorbid Condition. Diabetes. 2025;74(Supplement_1):2189-LB. doi:10.2337/db25-2189-LB
2. Tran LL. 143-OR: NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss. Diabetes. 2025;74(Supplement_1):143-OR. doi:10.2337/db25-143-OR
3. Tran LL, Vu F, Tran ZV. SAT-713 Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese with at Least One Weight-related Comorbid Condition. Journal of the Endocrine Society. 2025;9(Supplement_1):bvaf149.144. doi:10.1210/jendso/bvaf149.144
4. Biomed Industries, Inc. A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of NA-931 for Weight Management in Subjects Who Are Obese or Overweight With at Least One Weight-related Comorbid Condition.
5. Biomed Industries, Inc. A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of NA-931 in Overweight/Obese Participants and in Patients With Type 2 Diabetes Mellitus.
6. Tran LL. Phase 1 Clinical Trials Results of NA-931, a Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist for the Treatment of Obesity. Endocr Pract. 2025. doi:10.1016/j.eprac.2025.08.015